



Published in final edited form as:

J Neurosci. 2007 April 18; 27(16): 4253–4260. doi:10.1523/JNEUROSCI.0211-07.2007.

Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia

Yi-Bing Ouyang, Ludmila A. Voloboueva, Li-Jun Xu, and Rona G. Giffard

Department of Anesthesia, Stanford University School of Medicine, Stanford, CA 94305

Abstract

Transient global ischemia, as with cardiac arrest, causes loss of CA1 hippocampal neurons 2–4 days later, while nearby dentate gyrus (DG) neurons are relatively resistant. Whether differential astrocyte vulnerability to ischemic injury contributes to CA1 neuronal death is uncertain. Here we find that CA1 astrocytes are more sensitive to ischemia than DG astrocytes. In rats subjected to transient forebrain ischemia, CA1 astrocytes lose glutamate transport activity and immunoreactivity for GFAP, S100 β and glutamate transporter GLT-1, within a few hours of reperfusion, but without astrocyte cell death. Oxidative stress may contribute to the observed selective CA1 changes as CA1 astrocytes show early increases in mitochondrial free radicals and reduced mitochondrial membrane potential. Similar changes were not observed in DG astrocytes. Upregulation of GLT-1 expression in astrocytes with ceftriaxone protected CA1 neurons from forebrain ischemia. We suggest that greater oxidative stress and loss of GLT-1 function selectively in CA1 astrocytes is central to the well known delayed death of CA1 neurons.

Keywords

astrocyte; global ischemia; glutamate transporter; hippocampus; mitochondria; oxidative stress

Introduction

Global cerebral ischemia, as seen with cardiac arrest, causes delayed loss of CA1 pyramidal neurons while the nearby dentate gyrus (DG) area is relatively resistant. Patients who survive cardiac arrest face significant neurological disability due to loss of CA1 neurons. Thus far only hypothermia has been shown to improve neurological outcome in these patients (Bernard et al., 2002; Group, 2002). In animals, transient forebrain ischemia has been used as global ischemia model and also causes delayed neuronal death selectively in hippocampal CA1 pyramidal neurons after 2–4 days of reperfusion while DG, CA3, and most cortical neurons remain essentially intact (Kirino, 1982; Pulsinelli, 1985). For many years selective neuronal vulnerability has been presumed to reflect the inherent vulnerability and connectivity of the neuronal population. However, progress delineating these mechanisms has not been able to fully explain the long recognized selectivity of ischemic neuronal loss. We postulate that differences in astrocyte vulnerability are central to this regional neuronal loss.

Astrocytes are the most numerous cell type in the brain, dynamically involved in synaptic transmission, metabolic and ionic homeostasis, inflammatory response, antioxidant defense, trophic support of neurons, as well as in the establishment and maintenance of the blood brain barrier (Kettenmann and Ransom, 2005). Hippocampal astrocytes occupy exclusive, non-overlapping territories (Bushong et al., 2002), a pattern that develops in the early postnatal period in parallel with neuronal and vascular territories (Bushong et al., 2004). Astrocytes respond to signals from and signal actively to neurons, endothelium, and microglia (for reviews see (Ransom et al., 2003; Volterra and Meldolesi, 2005)). Recent work has demonstrated a protective role of reactive astrocytes after spinal cord injury (Faulkner et al., 2004). One protective function of astrocytes during ischemia is glutamate uptake to limit excitotoxic injury of neighboring neurons (Rosenberg and Aizenman, 1989; Dugan et al., 1995). Glutamate excitotoxicity is one major mechanism underlying ischemic damage in the central nerve system (Benveniste, 1991; Choi, 1994; Siesjo et al., 1995; Swanson et al., 2004). Failure of uptake as well as release of glutamate by impaired astrocytes is thought to contribute to ischemic neuronal injury (Swanson et al., 2004).

In this paper we investigated the early astrocyte response to ischemic injury comparing the selectively vulnerable CA1 region with the more resistant DG. This study provides evidence for the novel hypothesis that selective hippocampal astrocytic impairment is responsible for the selective loss of CA1 hippocampal neurons following global or forebrain ischemia. We demonstrate for the first time differential responses of astrocytes from different hippocampal subregions to ischemia: in generation of reactive oxygen species, changes in mitochondrial membrane potential, and glutamate uptake. We furthermore show that dramatic loss of GFAP immunoreactivity is not associated with astrocyte death. We provide evidence that early loss of glutamate transport contributes to neuronal loss as induction of higher GLT-1 levels in astrocytes prior to ischemia reduces neuronal death in slice and *in vivo*.

Materials and Methods

Forebrain ischemia, drug treatment and assessment

All experiments using animals were performed in accordance with a protocol approved by the Stanford University animal care and use committee, and in keeping with the National Institutes of Health guide. Forebrain ischemia in rats was induced with the 2-vessel occlusion plus hypotension model (Smith et al., 1984) with some modifications. In brief, male Sprague Dawley rats, weighing 270–330 g were anesthetized by face mask with isoflurane in oxygen:N₂O(3:7). Hypotension (to 50 mm Hg) was induced by removing blood through the jugular vein into heparinized sterile tubing before carotid clamping. At the end of 10 min bilateral carotid occlusion recirculation was induced by reinfusing the shed blood and by releasing the clamps placed around the carotid arteries. At various time points following recirculation, rats were sacrificed and the brains removed. The treatment group was injected daily with ceftriaxone (i.p, 200 mg/kg for 5 days, see (Rothstein et al., 2005)) before 10 min forebrain ischemia.

Before removal, brains were perfused with saline then ice-cold 4% phosphate buffered paraformaldehyde. Coronal sections were made with a Vibratome at a thickness of 35 μ m for immunohistochemistry or staining with cresyl violet to assess injury. In other experiments acute brain slices obtained following global ischemia were stained with sulforhodamine 101 (SR101) (Nimmerjahn et al., 2004); SR101 (2 μ M) was dissolved in cell culture medium and applied for 5 min followed by two washes before observation.

Primary astrocyte cultures and organotypic brain slice cultures

Primary astrocyte cultures were prepared from postnatal (days 1–3) Swiss Webster mice (Simonsen, Gilroy, CA) as previously described (Dugan et al., 1995; Xu et al., 2001; Ouyang et al., 2006). Subregions of hippocampus were isolated as described by Chen and colleagues (Chen et al., 2005). In brief, hippocampi were isolated, the dorsal region of the hippocampus containing primarily CA1 (Chen et al., 2005) was dissected free of the rest of the hippocampus. The ventral hippocampus containing DG was further reduced by removal of the CA3 region. Cultures were maintained at 37°C in a 5% CO₂ incubator. The organotypic slice cultures were prepared as previously described (Ouyang et al., 2005).

Injury paradigms and assessment

Two insults were studied in astrocyte and slice cultures. Glucose deprivation (GD) was done by removing glucose from the medium (Ouyang et al., 2006). Combined oxygen glucose deprivation (OGD) was done in slice culture by anoxic exposure in medium meant to replicate ischemic extracellular fluid as described (Ouyang et al., 2005). For primary cultures we used OGD to mimic ischemia (Xu et al., 2001). Ceftriaxone pretreatment of slice cultures was 100 μM for 5 days before OGD.

Cell death in primary astrocyte cultures was detected with the fluorescent cell death markers propidium iodide (PI) or SYTOX green. In hippocampal slice cultures cell death was assessed by measuring mean fluorescence intensity of PI in a standardized area in the CA1 region subtracting the fluorescence in a square placed in an undamaged area outside the CA2/CA3 cell band (background) as described (Ouyang et al., 2005).

Immunohistochemistry and Western blots

After experiments, cell and hippocampal slice cultures were fixed with 4% phosphate buffered paraformaldehyde. Fluorescence immunohistochemistry was performed as previously described (Ouyang et al., 2005) using antibodies against GFAP, GLT-1, S100β and GLAST (Chemicon, Temecula, CA). Western blots were performed using anti-GFAP and anti-GLT-1 antibodies.

Glutamate uptake

Glutamate uptake was measured according to published methods (Vesce et al., 1997; Brooke and Sapolsky, 2003) using aspartate. Aspartate is taken up by the same transporters with a similar K_d to glutamate but is not further metabolized (Drejer et al., 1983). Briefly, after ischemia-like injury the cells were incubated in glucose-free medium with a mixture of ³H D-aspartate (0.5 μC/mL) and cold aspartate at 1 μM. After 7 min the cells were washed 4 times with ice-cold PBS containing the transport inhibitor 1 mM threo-B hydroxyaspartic acid, scraped with lysate buffer (1% Triton X-100) and counted by scintillation counter for incorporated radioactivity.

Mitochondrial membrane potential and oxygen radical production

Live cell imaging studies were performed as previously described (Ouyang et al., 2006) with some modifications. We used TMRE to assess mitochondrial membrane potential, and MitoSOX Red or H₂O₂ to assess oxygen radical production. Fluorescence changes were quantified (Ouyang et al., 2006) by selecting a cytoplasmic region of each cell that was strongly fluorescent at baseline and normalizing subsequent fluorescence measurements to the basal fluorescence (F₀) for each cell at the start of the experiment.

Statistics

All data represent at least 3 independent experiments. Data are reported as mean \pm SD. Statistical differences were determined using ANOVA followed by Scheffes or Tukey test with $p < 0.05$ the level considered significant (using StatView by SAS Institute, Inc. or Instat from GraphPad Software).

Results

Differences in immunoreactivity between CA1 and DG astrocytes after transient *in vivo* and *in vitro* ischemia

To define early changes in CA1 astrocytes we performed immunohistochemical studies at early reperfusion times in rats subjected to 10 min forebrain ischemia. We evaluated immunoreactivity for GFAP (Fig. 1A), an astrocyte specific intermediate filament protein, and for the astrocytic glutamate transporter GLT-1 (Fig. 1B) which plays a key role in limiting neuronal excitotoxicity. There were obvious differences observed between CA1 and DG. At 5 h and 12 h of reperfusion there was a marked reduction in GFAP staining of astrocytes in the CA1 region, while the neuronal layer still looked normal (Fig. 1A). By 2 d of reperfusion, there was clear evidence of astrocyte activation and hypertrophy with increased GFAP staining and the relative disappearance of the CA1 neuronal cell body layer evident in the PI stained panel. The GFAP immunostaining in DG was not lost at early reperfusion intervals (Fig. 1A); though Western blot did show some reduction at 5 h of reperfusion (Fig. 1C) which was less than the reduction observed in CA1. At 5 h reperfusion after 10 min forebrain ischemia we saw a marked reduction of GLT-1 staining in CA1 but not in DG (Fig. 1B). This was confirmed by Western blot of GLT-1 protein that demonstrated the characteristic wide poorly defined bands (Fig. 1C) at ~65 kDa (Danbolt, 2001). In our studies GLT-1 staining in the CA1 region remained reduced for up to 24 h of reperfusion, with slow recovery to control values after 2–3 days of reperfusion (data not shown). Hippocampal slices subjected to transient *in vitro* ischemia (oxygen glucose deprivation, OGD) (Fig. 1D) exhibited reduced GLT-1 immunoreactivity at early recovery (2 h) after 15 min OGD in the CA1 region, while the DG region still showed strong staining, similar to the *in vivo* observations.

We took advantage of sub-regional primary cultures of astrocytes to examine in greater detail the effects of varying ischemic severity (Fig. 2A). Astrocytes isolated from CA1 lost GLT-1 staining by the end of 1 h ischemia (OGD) with modest reduction of GFAP labeling. At 5 h recovery GFAP staining was almost gone from CA1 astrocytes, while DG astrocytes still had no significant changes. Although there were no changes of GLT-1 or GFAP staining in DG astrocytes after 1 h OGD, after 2 h OGD and 2 h recovery GLT-1 was decreased in DG astrocytes. GFAP staining, which was markedly decreased in CA1, was still normal in DG astrocytes despite the more severe insult. In summary, we observed that decreased immunoreactivity for GLT-1 occurred first, followed by loss of GFAP immunoreactivity in both CA1 and DG astrocytes, but less severe insults induced these changes in CA1 astrocytes. Greater vulnerability of CA1 astrocytes was observed in all three models of ischemic hippocampal injury. This suggests that the greater sensitivity is in part intrinsic to CA1 astrocytes, since it was still present in culture in the absence of neurons. Since immunoreactivity does not report directly about function, we further investigated glutamate transport activity. As shown in Fig. 2B, a significant decrease of more than 40% in the rate of glutamate uptake by CA1 astrocyte cultures was observed after 2 h of OGD followed by 2 h of recovery, assessed by ^3H aspartate uptake. The same treatment induced no significant change in uptake by DG cultures.

To determine whether the rapid decrease of GLT-1 and GFAP staining is accompanied by disappearance of other immunocytochemical epitopes in CA1 astrocytes, we tested additional astrocytic markers at 5 h after 1 h OGD (Fig. 2C). Both S100 β , a calcium binding protein, and GFAP immunolabeling were markedly decreased at 5 h recovery (Fig. 2C). On the other hand immunostaining for GLAST, another astrocytic glutamate transporter, did not change much at this time point (Fig. 2C), consistent with other reports (Yeh et al., 2005). This suggested that astrocytes were not dead since some astrocytic markers remained unchanged.

CA1 astrocyte death is minimal when GFAP and GLT-1 immunoreactivity is reduced following ischemia

Whether significant astrocyte death occurs following global ischemia *in vivo* as well as in slice and culture models is an important question. We demonstrated, based on reports in the literature (Nimmerjahn et al., 2004), that SR101, an astrocyte specific dye, is taken up by live but not dead astrocytes (Fig. 3A). We found that there was no significant increase in either apoptotic or necrotic death in CA1 astrocytic cultures after insults that reduced GFAP and GLT-1 immunoreactivity (Fig. 3B). Similar observations were made in acute slices of CA1 region following 10 min global ischemia *in vivo* (Fig. 3C, D and E) by sulforhodamine 101 (SR101) staining.

Possible mechanisms of selective CA1 astrocyte dysfunction-oxidative stress and mitochondrial dysfunction

GLT-1 is susceptible to oxidative damage (Lauderback et al., 2001). To test the hypothesis that differential mitochondrial response to stress and generation of reactive oxygen species (ROS) could contribute to the differential response of astrocytes from the two regions we used cultured astrocytes isolated from the CA1 and DG regions and monitored mitochondrial membrane potential using tetramethylrhodamine ethylester (TMRE) (Fig. 4A), and generation of ROS using MitoSOX red (Fig. 4B) and hydroethidine (HEt) (Fig. 4C). CA1 astrocytes were more susceptible to reduction of mitochondrial membrane potential and increased generation of ROS compared to DG astrocytes challenged with the same insult. As shown in Fig. 4A, after 1 h glucose deprivation (GD) the TMRE signal from DG astrocytes was constant, while the signal from CA1 astrocytes was reduced about 15%, indicating partial mitochondrial depolarization. The use of the mitochondrially localized ROS sensitive dye MitoSOX red (Fig. 4B) showed increased ROS in CA1, but not in DG astrocytes after 15 min GD. After 30 min, the oxidized dye appeared to move into nuclei, and this occurred earlier in CA1 compared to DG astrocytes. We also used HEt to detect ROS (Fig. 4C). After 1 h GD, the HEt signal about doubled in DG astrocytes, while in CA1 astrocytes it was significantly higher, reaching about 3.5 times the fluorescence intensity at baseline (Fig. 4C).

One of the major sites of ROS production in cells is the mitochondrial respiratory chain (Turrens and Boveris, 1980). To further investigate the relationship between activity of GLT-1 and mitochondrially generated ROS, we exposed cultured CA1 and DG astrocytes to rotenone, a classical inhibitor of mitochondrial complex I. After loading the astrocytes with HEt, control images were taken and then rotenone (50 nM) was added. After 30 min of rotenone exposure there was a significant increase of HEt fluorescence and obvious decrease in GLT-1 immunostaining at the same time (Fig. 4D) in both CA1 and DG astrocytes. These results indicate that the greater generation of ROS from mitochondria observed in CA1 astrocytes after ischemia may contribute to the loss of GLT-1.

Up-regulation of astrocytic GLT-1 decreases CA1 neuronal death

A report from Rothstein et al. (Rothstein et al., 2005) demonstrated that the β -lactam antibiotic ceftriaxone could upregulate GLT-1 in astrocytes, and resulted in some protection from excitotoxicity *in vitro* and from a model of amyotrophic lateral sclerosis *in vivo*. We therefore tested ceftriaxone and found that it did induce higher expression of GLT-1 in CA1 in hippocampal slice culture treated with 100 μ M of ceftriaxone for 5 days (Fig. 5A). Note that in the slice control GLT-1 staining shows a typical astrocytic pattern leaving the neuronal cell body layer relatively unstained. When over-expressed after drug treatment, astrocyte staining was so bright in CA1 that the neuronal cell body layer was relatively obscured. We found pretreatment with ceftriaxone reduced CA1 neuronal loss in slice cultures subjected to 15 min OGD followed by 24 h recovery (Fig. 5B and C). To determine whether this method of protection would also work *in vivo*, we pre-treated animals with ceftriaxone before subjecting them to 10 min forebrain ischemia. We found that treatment with ceftriaxone increased expression of GLT-1 in hippocampus (Fig. 5D) and reduced delayed CA1 neuronal death as shown by cresyl violet staining after 7 days of reperfusion (Fig. 5E and F). Thus increased GLT-1 expression in astrocytes results in decreased susceptibility of neighboring neurons to ischemic injury following brief forebrain ischemia.

Discussion

It is often said that neurons are the cells most vulnerable to ischemia. This view is based largely on observations that astrocytes in culture show greater resistance than neurons to some ischemia-like insults (Goldberg and Choi, 1993; Xu et al., 2001) and that as noted above, brief global ischemia results in apparently selective loss of neurons. However, vulnerability of cultured astrocytes is markedly increased by acidic conditions relevant to ischemic injury (Giffard et al., 1990; Bondarenko and Chesler, 2001). Several laboratories have now pointed out that glial cells may be injured more readily than previously thought, sometimes before neuronal damage is obvious (Petito et al., 1998; Liu et al., 1999; Zhao et al., 2003). Astrocytic processes were fragmented and mitochondria inhibited after 15 min exposure to acidic conditions in hippocampal slice cultures (Hulse et al., 2001). Astrocytic demise was found to precede delayed neuronal death following focal ischemia (Liu et al., 1999) and was observed early following traumatic brain injury (Zhao et al., 2003). Selective glial vulnerability was seen following transient global ischemia primarily involving oligodendrocytes (Petito et al., 1998). We previously observed that astrocytes, as well as neurons, isolated from different brain regions showed different responses to stress (Xu et al., 2001).

Though these studies suggest that astrocytic demise can precede neuronal death in some situations, there is relatively little information currently available about differences in astrocyte response to ischemia in the selectively vulnerable CA1 region of the hippocampus, compared to the less readily injured DG region. In the present study we investigated the early temporal and spatial profile of astrocyte changes in hippocampal CA1 and DG regions in response to ischemia. We demonstrated (1) more rapid decrease in GLT-1 immunoreactivity and glutamate uptake activity in CA1 astrocytes compared to DG astrocytes (2) that these early changes are functional, and are not accompanied by CA1 astrocyte death (3) that early increases in mitochondrial ROS in CA1 astrocytes may in part explain the loss of GLT-1 transport activity and (4) loss of GLT-1 is a relevant mechanism of CA1 neuronal injury since up-regulation of astrocytic GLT-1 decreased CA1 delayed neuronal death *in vitro* and *in vivo*.

To date, five brain glutamate transporters have been cloned, EAAT1-5. Of these, GLT-1/EAAT2 and GLAST/EAAT1 are expressed in astrocytes and play a crucial role in preventing glutamate excitotoxicity (Gegelashvili and Schousboe, 1997). Reduction or loss

of astroglial transporters, GLT-1 or GLAST, led to a tonic increase in extracellular glutamate concentration and subsequent neurodegeneration (Rothstein et al., 1996; Mitani and Tanaka, 2003). GLT-1 appears to be especially important in hippocampus as mice lacking GLT-1 showed spontaneous seizures, selective hippocampal neurodegeneration, and exacerbation of acute cortical injury (Tanaka et al., 1997), while mice deficient in GLAST were more susceptible to cerebellar injury (Watase et al., 1998). In addition, down regulation of glial EAAT1/GLAST or EAAT2/GLT-1 glutamate transporters but not the neuronal subtype EAAT3/EAAC1, has been shown to increase ischemic injury following focal cerebral ischemia in rats (Watase et al., 1998; Fukamachi et al., 2001; Rao et al., 2001).

Direct evidence has recently been provided that glial glutamate transporters are lost with hypoxia in the neonatal pig brain (Pow et al., 2004) and that hippocampal astrocytic glutamate uptake is impaired following global ischemia (Chen et al., 2005; Yeh et al., 2005). Our studies demonstrate, for the first time, that differential astrocytic glutamate transporter protein levels and activity contribute to the differential vulnerability of CA1 and DG regions to ischemia. Decrease in astrocyte glutamate uptake would likely be associated with increased susceptibility of neighboring neurons to excitotoxic injury. This provides a new variation on the old idea of excitotoxicity contributing to selective CA1 neuronal injury- we suggest that early loss of astrocyte glutamate uptake likely due in part to oxidative damage in CA1 astrocytes, contributes to the selective vulnerability of CA1 neurons.

This mechanism is reminiscent of that suggested to occur in amyotrophic lateral sclerosis. Work by Weiss and colleagues showed that motor neurons only died after glutamate transport activity was lost in astrocytes surrounding the neurons (Rao et al., 2003). This work suggested that oxidative stresses, possibly emanating from neurons, eventually compromised astrocyte function, which then precipitated neuronal death. Oxidative stress has also been shown to downregulate astrocytic glutamate uptake in ammonia-induced toxicity (Jayakumar et al., 2006). In CA1 following global ischemia increased generation of ROS, possibly in part due to CA1 neurons, but also, as suggested here, originating in astrocytes, compromises astrocyte function which in turn compromises the ability of the CA1 pyramidal neurons to survive.

Mitochondrial dysfunction has been implicated in the selective vulnerability of CA1 cells after ischemia, since cell death in this region following global ischemia is inhibited by Cyclosporin A, a known inhibitor of the calcium-induced mitochondrial permeability transition in brain mitochondria (Uchino et al., 1995). The observation that Cyclosporin A can protect mitochondria from calcium insult in astrocytes but not in neurons (Bambrick et al., 2006) suggests astrocyte mitochondria are central to protection by this drug *in vivo*. The mechanism of selective CA1 astrocyte dysfunction we propose here is due to differences in mitochondrial response, leading to greater production of ROS in CA1 astrocytes. This leads to greater energetic compromise, oxidative damage, and loss of GLT-1 function. Oxidative stress is known to contribute to damage and misfolding of proteins, including glutamate transporters (Lauderback et al., 2001). The impaired CA1 astrocytes may be unable to carry out many of their normal functions- glutamate uptake, antioxidant defense, regulation of extracellular ions etc. Consistent with our results is a report from Mattiason et al. (Mattiasson et al., 2003) who found that isolated mitochondria from the hippocampal CA1 subregion produced more ROS and were more sensitive to calcium-induced swelling than mitochondria isolated from the adjacent subregion, CA3 (Mattiasson et al., 2003). This work, however, did not separate neurons and astrocytes.

In conclusion, our study indicates that early changes in CA1 astrocyte immunoreactivity and function precede the degeneration of CA1 neurons by more than a day, so selective

vulnerability of CA1 neurons may be secondary to selective ischemia-induced astrocyte dysfunction. It suggests that greater attention should be paid to developing strategies to protect normal astrocyte physiology and function which could be a useful approach to neuroprotection following cardiac arrest.

Acknowledgments

This work was supported in part by NIH grants GM49831, NS014543 and NS37520 to RGG. We thank Heng Zhao for help with the global ischemia model, Bruce Winegar and Bruce MacIver for help with acute hippocampal slices and Robert Sapolsky and Shiela Brooks for help with the glutamate uptake assays.

References

- Bambrick LL, Chandrasekaran K, Mehrabian Z, Wright C, Krueger BK, Fiskum G. Cyclosporin a increases mitochondrial calcium uptake capacity in cortical astrocytes but not cerebellar granule neurons. *J Bioenerg Biomembr.* 2006; 38:43–47. [PubMed: 16786428]
- Benveniste H. The excitotoxin hypothesis in relation to cerebral ischemia. *Cerebrovasc Brain Metab Rev.* 1991; 3:213–245. [PubMed: 1931486]
- Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med.* 2002; 346:557–563. [PubMed: 11856794]
- Bondarenko A, Chesler M. Rapid astrocyte death induced by transient hypoxia, acidosis, and extracellular ion shifts. *Glia.* 2001; 34:134–142. [PubMed: 11307162]
- Brooke SM, Sapolsky RM. Effects of glucocorticoids in the gp120-induced inhibition of glutamate uptake in hippocampal cultures. *Brain Res.* 2003; 972:137–141. [PubMed: 12711086]
- Bushong EA, Martone ME, Ellisman MH. Maturation of astrocyte morphology and the establishment of astrocyte domains during postnatal hippocampal development. *Int J Dev Neurosci.* 2004; 22:73–86. [PubMed: 15036382]
- Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J Neurosci.* 2002; 22:183–192. [PubMed: 11756501]
- Chen JC, Hsu-Chou H, Lu JL, Chiang YC, Huang HM, Wang HL, Wu T, Liao JJ, Yeh TS. Down-regulation of the glial glutamate transporter GLT-1 in rat hippocampus and striatum and its modulation by a group III metabotropic glutamate receptor antagonist following transient global forebrain ischemia. *Neuropharmacology.* 2005; 49:703–714. [PubMed: 16019039]
- Choi DW. Glutamate receptors and the induction of excitotoxic neuronal death. *Prog Brain Res.* 1994; 100:47–51. [PubMed: 7938533]
- Danbolt NC. Glutamate uptake. *Prog Neurobiol.* 2001; 65:1–105. [PubMed: 11369436]
- Drejer J, Larsson OM, Schousboe A. Characterization of uptake and release processes for D- and L-aspartate in primary cultures of astrocytes and cerebellar granule cells. *Neurochem Res.* 1983; 8:231–243. [PubMed: 6856028]
- Dugan LL, Bruno VM, Amagasu SM, Giffard RG. Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. *J Neurosci.* 1995; 15:4545–4555. [PubMed: 7540679]
- Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. *J Neurosci.* 2004; 24:2143–2155. [PubMed: 14999065]
- Fukamachi S, Furuta A, Ikeda T, Ikenoue T, Kaneoka T, Rothstein JD, Iwaki T. Altered expressions of glutamate transporter subtypes in rat model of neonatal cerebral hypoxia-ischemia. *Brain Res Dev Brain Res.* 2001; 132:131–139.
- Gegelashvili G, Schousboe A. High affinity glutamate transporters: regulation of expression and activity. *Mol Pharmacol.* 1997; 52:6–15. [PubMed: 9224806]
- Giffard RG, Monyer H, Choi DW. Selective vulnerability of cultured cortical glia to injury by extracellular acidosis. *Brain Res.* 1990; 530:138–141. [PubMed: 2176914]

- Goldberg MP, Choi DW. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. *J Neurosci.* 1993; 13:3510–3524. [PubMed: 8101871]
- Group THACAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med.* 2002; 346:549–556. [PubMed: 11856793]
- Hulse RE, Winterfield J, Kunkler PE, Kraig RP. Astrocytic clasmotodendrosis in hippocampal organ culture. *Glia.* 2001; 33:169–179. [PubMed: 11180514]
- Jayakumar AR, Panickar KS, Murthy Ch R, Norenberg MD. Oxidative stress and mitogen-activated protein kinase phosphorylation mediate ammonia-induced cell swelling and glutamate uptake inhibition in cultured astrocytes. *J Neurosci.* 2006; 26:4774–4784. [PubMed: 16672650]
- Kettenmann, H.; Ransom, B. *Neuroglia*, Second Edition. New York: Oxford University Press; 2005.
- Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. *Brain Res.* 1982; 239:57–69. [PubMed: 7093691]
- Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. *J Neurochem.* 2001; 78:413–416. [PubMed: 11461977]
- Liu D, Smith CL, Barone FC, Ellison JA, Lysko PG, Li K, Simpson IA. Astrocytic demise precedes delayed neuronal death in focal ischemic rat brain. *Brain Res Mol Brain Res.* 1999; 68:29–41. [PubMed: 10320781]
- Mattiasson G, Friberg H, Hansson M, Elmer E, Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. *J Neurochem.* 2003; 87:532–544. [PubMed: 14511130]
- Mitani A, Tanaka K. Functional changes of glial glutamate transporter GLT-1 during ischemia: an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. *J Neurosci.* 2003; 23:7176–7182. [PubMed: 12904478]
- Nimmerjahn A, Kirchhoff F, Kerr JN, Helmchen F. Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. *Nat Methods.* 2004; 1:31–37. [PubMed: 15782150]
- Ouyang YB, Xu L, Giffard RG. Geldanamycin treatment reduces delayed CA1 damage in mouse hippocampal organotypic cultures subjected to oxygen glucose deprivation. *Neurosci Lett.* 2005; 380:229–233. [PubMed: 15862891]
- Ouyang YB, Xu LJ, Sun YJ, Giffard RG. Overexpression of inducible heat shock protein 70 and its mutants in astrocytes is associated with maintenance of mitochondrial physiology during glucose deprivation stress. *Cell Stress Chaperones.* 2006; 11:180–186. [PubMed: 16817324]
- Petito CK, Olarte JP, Roberts B, Nowak TS Jr, Pulsinelli WA. Selective glial vulnerability following transient global ischemia in rat brain. *J Neuropathol Exp Neurol.* 1998; 57:231–238. [PubMed: 9600215]
- Pow DV, Naidoo T, Lingwood BE, Healy GN, Williams SM, Sullivan RK, O'Driscoll S, Colditz PB. Loss of glial glutamate transporters and induction of neuronal expression of GLT-1B in the hypoxic neonatal pig brain. *Brain Res Dev Brain Res.* 2004; 153:1–11.
- Pulsinelli WA. Selective neuronal vulnerability: morphological and molecular characteristics. *Prog Brain Res.* 1985; 63:29–37. [PubMed: 2872695]
- Ransom B, Behar T, Nedergaard M. New roles for astrocytes (stars at last). *Trends Neurosci.* 2003; 26:520–522. [PubMed: 14522143]
- Rao SD, Yin HZ, Weiss JH. Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. *J Neurosci.* 2003; 23:2627–2633. [PubMed: 12684448]
- Rao VL, Dogan A, Todd KG, Bowen KK, Kim BT, Rothstein JD, Dempsey RJ. Antisense knockdown of the glial glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. *J Neurosci.* 2001; 21:1876–1883. [PubMed: 11245672]
- Rosenberg PA, Aizenman E. Hundred-fold increase in neuronal vulnerability to glutamate toxicity in astrocyte-poor cultures of rat cerebral cortex [published erratum appears in *Neurosci Lett* 1990 Aug 24;116(3):399]. *NeurosciLett.* 1989; 103:162–168.

- Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. *Neuron*. 1996; 16:675–686. [PubMed: 8785064]
- Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. *Nature*. 2005; 433:73–77. [PubMed: 15635412]
- Siesjo BK, Katsura K, Zhao Q, Folbergrova J, Pahlmark K, Siesjo P, Smith ML. Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. *J Neurotrauma*. 1995; 12:943–956. [PubMed: 8594224]
- Smith ML, Bendek G, Dahlgren N, Rosen I, Wieloch T, Siesjo BK. Models for studying long-term recovery following forebrain ischemia in the rat. 2. A 2-vessel occlusion model. *Acta Neurol Scand*. 1984; 69:385–401. [PubMed: 6464670]
- Swanson RA, Ying W, Kauppinen TM. Astrocyte influences on ischemic neuronal death. *Curr Mol Med*. 2004; 4:193–205. [PubMed: 15032713]
- Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science*. 1997; 276:1699–1702. [PubMed: 9180080]
- Turrens JF, Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. *Biochem J*. 1980; 191:421–427. [PubMed: 6263247]
- Uchino H, Elmer E, Uchino K, Lindvall O, Siesjo BK. Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. *Acta Physiol Scand*. 1995; 155:469–471. [PubMed: 8719269]
- Vesce S, Bezzi P, Rossi D, Meldolesi J, Volterra A. HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid. *FEBS Lett*. 1997; 411:107–109. [PubMed: 9247152]
- Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. *Nat Rev Neurosci*. 2005; 6:626–640. [PubMed: 16025096]
- Watase K, Hashimoto K, Kano M, Yamada K, Watanabe M, Inoue Y, Okuyama S, Sakagawa T, Ogawa S, Kawashima N, Hori S, Takimoto M, Wada K, Tanaka K. Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. *Eur J Neurosci*. 1998; 10:976–988. [PubMed: 9753165]
- Xu L, Sapolsky RM, Giffard RG. Differential sensitivity of murine astrocytes and neurons from different brain regions to injury. *Exp Neurol*. 2001; 169:416–424. [PubMed: 11358455]
- Yeh TH, Hwang HM, Chen JJ, Wu T, Li AH, Wang HL. Glutamate transporter function of rat hippocampal astrocytes is impaired following the global ischemia. *Neurobiol Dis*. 2005; 18:476–483. [PubMed: 15755674]
- Zhao X, Ahran A, Berman RF, Muizelaar JP, Lyeth BG. Early loss of astrocytes after experimental traumatic brain injury. *Glia*. 2003; 44:140–152. [PubMed: 14515330]




Figure 1. Forebrain ischemia-induced changes in GFAP and GLT-1 immunoreactivity in CA1 and DG hippocampal regions

A, GFAP immunostaining in the hippocampal CA1 and DG regions of rats subjected to 10 min forebrain ischemia followed by the indicated durations of reperfusion (R). Green is GFAP immunoreactivity while red is propidium iodide (PI) staining for nuclei. GFAP staining was strikingly decreased during early reperfusion in CA1 compared to DG. Scale bars: 80 μ m for upper panel; 60 μ m for lower panel. **B**, Changes in GLT-1 staining in hippocampal CA1 and DG regions of a rat subjected to 10 min forebrain ischemia followed by 5 h recovery (R). Scale bar: 40 μ m. **C**, Quantification of the changes by Western blot in GFAP and GLT-1 staining in hippocampal CA1 and DG regions of rats subjected to 10 min forebrain ischemia followed by 5 h recovery (R), $n=3$, * $p < 0.05$ indicates statistically different from control for the same region. Each lane shows protein from a different animal. **D**, GLT-1 immunoreactivity in hippocampal CA1 and DG regions of organotypic hippocampal brain slices subjected to 15 min OGD followed by 2 h recovery. Scale bars: 2 mm for the left panel of each group and 25 μ m for the two right panels. Ctrl: control group.




Figure 2. GFAP, GLT-1, S100 β and GLAST immunoreactivity and glutamate uptake in astrocytes from CA1 and DG hippocampal regions after OGD
A, Comparison of GFAP and GLT-1 immunostaining with different durations of OGD and recovery time. Green: GLT-1, red: GFAP, blue: Hoechst for nuclei (for better contrast, the nuclei were pseudocolored red in the GLT-1 stained columns). Scale bar: 20 μ m. **B**, Changes in glutamate uptake activity in cultured astrocytes from hippocampal CA1 and DG regions after 2 h of OGD followed by 1 h of recovery. Values of glutamate uptake are a ratio to control and expressed as mean \pm SD of three separate experiments, each performed in triplicate (* $P < 0.05$ compared to CA1 at 0 h time point). **C**, Comparison of GFAP, S100 β (left two panels) and GLAST (right two panels) immunoreactivity at 5 h recovery (R) after 1 h OGD in astrocytes from hippocampal CA1 region. Green: S100 β and GLAST, red: GFAP, yellow: overlap. Scale bar: 60 μ m. Ctrl: control group.




Figure 3. Astrocytic viability at times corresponding to the loss of GFAP and GLT-1 staining
A, SYTOX green specifically labels nuclei of dead cells in mildly injured primary cortical astrocyte cultures, while SR101 red staining is only observed in viable cells that exclude SYTOX green (left panel). SR101 red staining colocalizes with the viability dye calcein green (resulting in yellow) in live cells; cell nuclei are stained with Hoechst (blue) (right panel). Scale bars: 100 μ m. **B**, Primary astrocyte cultures from CA1 region subjected to ischemic injury sufficient to induce loss of GLT-1 and GFAP immunostaining do not demonstrate signs of apoptotic or necrotic cell death. Quantitation of cell death in astrocytic primary cultures following 2 and 3 h OGD (3 independent experiments, n=600–700 cells per condition). The cells were stained with propidium iodide and poly-caspases green fluorescent substrate to count necrotic and apoptotic cells, respectively, after 2 h of reperfusion. **C**, SR101 staining and nuclear DAPI staining of brain sections from controls and rats subjected to 10 min of global ischemia (GI) and 5 h of reperfusion (R). Ctrl: control group. Acute slices subjected to a lethal insult (1 h OGD) demonstrate no SR101 astrocytic staining. **D**, Higher power views of 300 \times 600 μ m box indicated in CA1 regions show similar SR101 staining of viable astrocytes in GI and uninjured control. **E**, Quantification of astrocyte viability by SR101 staining in CA1 regions from rats subjected to dense forebrain ischemia/global ischemia (GI), sham control (Ctrl), and lethally injured acute hippocampal sections. Average SR101 intensity was measured in similarly positioned 300 \times 600 μ m areas of CA1 of 400 μ m acute hippocampal slices -2.8 mm to -4.4 mm Bregma, 7 sections per condition from 3 or 4 animals per condition.




Figure 4. Mitochondrial changes after glucose deprivation

A, Changes in TMRE fluorescence with 1 h glucose deprivation (GD) in cultured astrocytes. Left panels, micrographs of representative fields. **B**, Changes in mitochondrial ROS indicated by live imaging of MitoSOX Red fluorescence during GD in cultured astrocytes. CA1 astrocytes: left panels, DG: right panels. **C**, Changes in ROS indicated by hydroethidine (HET) fluorescence during GD in cultured astrocytes. Left panels, representative micrographs. Graph: means of 10–15 cells/condition. * $P < 0.05$ statistically different from CA1 0 h time point and from DG at the same time point using ANOVA followed by Scheffes test. **D**, Rotenone (50 nM) induced mitochondrial production of ROS and decrease GLT-1 immunostaining in CA1 subregion astrocytes. Red: HET, green: GLT-1, Rot: rotenone and Ctrl: control group. Scale bar: 25 μm .




Figure 5. Ceftriaxone induces GLT-1 expression and reduces CA1 delayed neuronal injury in hippocampal slice culture and *in vivo*

A, Ceftriaxone pretreatment (+Cef, 100 μ M for 5 days) strongly induces expression of GLT-1 immunoreactivity (green) in hippocampal slice cultures, especially in CA1 subregion, compared to vehicle treated control (-Cef). **B**, Bar graph shows the significant reduction of CA1 neuronal damage in ceftriaxone-treated (+Cef) slices compared to vehicle treated (-Cef) ones by relative PI fluorescence in hippocampal slice culture 24 h following 15 min OGD. $N=9$ slices per condition. * $P < 0.05$ indicates significant difference from control. **C**, Fluorescence images of representative PI-stained (red) hippocampal slices 24 h following 15 min OGD. Decreased PI fluorescence indicates decreased CA1 neuronal death in ceftriaxone -treated (+Cef) slices compared to vehicle treated (-Cef) ones. Scale bar: 400 μ m. **D**, Pretreatment of rats with ceftriaxone (200 mg/kg i.p, daily for 5 days) strongly induces expression of GLT-1 throughout the hippocampus. **E**, Bar graph shows the reduction of CA1 neuronal damage in ceftriaxone-treated (+Cef) animals compared to vehicle treated (-Cef) rats by cresyl violet staining intensity. **F**, Cresyl violet staining of representative brain slices from control and ischemic rats pre-treated with ceftriaxone (+Cef) or vehicle (-Cef). More pyramidal neurons were present in ceftriaxone treated brain after cresyl violet staining compared to those in the vehicle treated group after 7 days reperfusion ($n=4$ in each group. * $P < 0.05$ significantly different from control).